Yunpeng Liu

机构：First Hospital of China Medical University, China Medical University · ORCID：0000-0002-9645-7990

发表论文 157 篇 · 总被引 2431 次 · h-index 26

代表论文

• CXCL12+ tumor-associated endothelial cells promote immune resistance in hepatocellular carcinoma (2024 · Journal of Hepatology · 被引 65)
• Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial (2025 · Gut · 被引 14)
• T-bet+CD8+ T cells govern anti-PD-1 responses in microsatellite-stable gastric cancers (2025 · Nature Communications · 被引 11)
• Hypoxia-induced LAMB2-enriched extracellular vesicles promote peritoneal metastasis in gastric cancer via the ROCK1-CAV1-Rab11 axis (2024 · Oncogene · 被引 10)
• Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study (2024 · The Lancet Respiratory Medicine · 被引 9)
• 1786O BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis (IA) of a randomized phase II study (2024 · Annals of Oncology · 被引 7)